Back to Resources

AstraZeneca’s Tagrisso Celebrates 10 Years in the European Lung Cancer Market in the First Half of 2026

Market Highlights

  • AstraZeneca celebrated 10 years of Tagrisso by highlighting its efficacy and safety in NSCLC, launched a new HCP campaign in select countries, and shared clinical data supporting Tagrisso plus platinum-pemetrexed in advanced EGFR-mutated NSCLC.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com

Get in Touch

Want to see what we can do for your organization? We’ll walk you through CDP, train your team, and stay close with ongoing support.

Contact us